Thiébaut R, Daucourt V, Mercié P, Ekouévi D K, Malvy D, Morlat P, Dupon M, Neau D, Farbos S, Marimoutou C, Dabis F
Unité INSERM 330, Institut de Santé Publique, d'Epidémiologie et de Développement, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
Clin Infect Dis. 2000 Dec;31(6):1482-7. doi: 10.1086/317477. Epub 2000 Nov 29.
The objective of this study was to estimate the prevalence of and risk factors for clinical lipodystrophy (LD) and metabolic disorders in human immunodeficiency virus (HIV) type 1-infected patients. A cross-sectional survey of the Aquitaine Cohort was performed in January 1999. The clinical diagnosis of LD was categorized as fat wasting (FW), peripheral fat accumulation (FA), and mixed syndromes (MS). Of the 581 patients studied, 61% were treated with protease inhibitors. The overall prevalence of LD was 38% (95% confidence interval [CI], 32-42): prevalence of FW was 16% (95% CI, 13-18); of FA, 12% (95% CI, 10-15); and of MS, 10% (95% CI, 8-13). The prevalences of metabolic abnormalities were 49% (95% CI, 44-53) for lipid disorders and 20% (95% CI, 17-23), for glucose disorders. Factors associated with LD were age (for FW and MS), male sex (for FW), AIDS stage (for MS), body mass index (for FW and FA), waist-to-hip ratio (for FA and MS), and duration of antiretroviral treatment (for FW).
本研究的目的是评估1型人类免疫缺陷病毒（HIV）感染患者临床脂肪代谢障碍（LD）和代谢紊乱的患病率及危险因素。1999年1月对阿基坦队列进行了横断面调查。LD的临床诊断分为消瘦型（FW）、外周脂肪堆积型（FA）和混合型综合征（MS）。在研究的581例患者中，61%接受了蛋白酶抑制剂治疗。LD的总体患病率为38%（95%置信区间[CI]，32 - 42）：FW的患病率为16%（95% CI，13 - 18）；FA的患病率为12%（95% CI，10 - 15）；MS的患病率为10%（95% CI，8 - 13）。代谢异常的患病率为：脂质紊乱49%（95% CI，44 - 53），葡萄糖紊乱20%（95% CI，17 - 23）。与LD相关的因素有年龄（与FW和MS相关）、男性（与FW相关）、艾滋病分期（与MS相关）、体重指数（与FW和FA相关）、腰臀比（与FA和MS相关）以及抗逆转录病毒治疗持续时间（与FW相关）。
